There are 2789 resources available
1553TiP - A phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patients with advanced or metastatic soft tissue sarcoma
Presenter: Christoph Schliemann
Session: ePoster Display
1667TiP - Durvalumab plus platinum-etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A Spanish phase IIIb single arm, real-world study
Presenter: Luis Paz-Ares
Session: ePoster Display
1668TiP - Phase Ib study of AMG 757, a half-life extended bispecific T-cell engager immuno-oncology therapy, combined with AMG 404, an anti-PD-1 antibody, in patients with small cell lung cancer (SCLC)
Presenter: Afshin Dowlati
Session: ePoster Display
1673P - Efficacy and safety of 5 mg olanzapine for the prevention of carboplatin-induced nausea and vomiting in patients with thoracic malignancies: A prospective multicenter phase II study
Presenter: Yukiyoshi Fujita
Session: ePoster Display
1674P - Does body mass index (BMI) affect the type of response to anamorelin (ANAM) over time? Focus on body composition and anorexia symptoms and concerns
Presenter: David Currow
Session: ePoster Display
1675P - Potential effect of adipose tissue distribution on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients (pts) receiving first-line pembrolizumab (PEMBRO)
Presenter: Ilaria Trestini
Session: ePoster Display
1676P - Nutritional assessment in the era of targeted therapies in advanced non-small cell lung cancer (aNSCLC) oncogene-addicted patients
Presenter: Anna Maria Morelli
Session: ePoster Display
1677P - Correlation between body mass index and anthropometric measurements obtained from routine CT-scans
Presenter: Santhanam Sundar
Session: ePoster Display